Table 6B.

Multiple comparisons of quality of life for patients with normal cognition.

Fixed effects (type III)	P-value	Significance	Variation (percentage)	F (DFn, DFd)
Time x receiving CBD or placebo	0.0139	*	4.777	F(2, 40) = 4.763
Timepoint	0.0204	*	4.530	F(1.820, 36.40) = 4.517
CBD or placebo	0.4301	Ns	2.241	F(1, 20) = 0.6486
Patients	< 0.0001	****	69.10	F(20, 40) = 6.889
Post-hoc tests
Multiple comparisons test	Adjusted P-value	Significance	Mean difference	95.00% CI of diff.
(i) Placebo—cannabidiol
Baseline	0.5987	Ns	5.900	−5.749 to 17.55
Week 4	0.5634	Ns	6.467	−6.232 to 19.16
Week 8	>0.9999	Ns	−3.233	−13.51 to 7.048
(ii) Placebo
Baseline vs. week 4	>0.9999	Ns	−2.167	−8.110 to 3.777
Baseline vs. week 8	>0.9999	Ns	−0.6667	−6.610 to 5.277
Week 4 vs. week 8	>0.9999	Ns	1.500	−4.443 to 7.443
(iii) Cannabidiol
Baseline vs. week 4	>0.9999	Ns	−1.600	−8.111 to 4.911
Baseline vs. week 8	0.0016	**	−9.800	−16.31 to −3.289
week 4 vs. week 8	0.0093	**	−8.200	−14.71 to −1.689
(iv) Overall comparison of time points
Baseline vs. week 4	0.8761	Ns	−1.883	−6.291 to 2.524
Baseline vs. week 8	0.0152	*	−5.233	−9.641 to −0.8257
Week 4 vs. week 8	0.1943	Ns	−3.350	−7.758 to 1.058

The ^*, ^**, ^***, and ^**** indicates the value of p < 0.05, p < 0.01, p < 0.001, and p < 0.0001 respectively.